Lexology April 17, 2024
McDermott Will & Emery

There have been 44 initial public offerings (IPOs) listed on the US stock markets in 2024 thus far, many of which continue to trade at a premium to their initial offering price, demonstrating the strength and buoyancy of current public markets. Concurrent with the capital markets regaining momentum, 2024 to date has shown robust merger and acquisition (M&A) activity, with notable growth of close to 11% in life sciences M&A activity compared to 2023. These developments are in line with the macro trends of lower inflation, wage stabilization and the potential promise of lower interest rates later in the year and continued strong sectoral interest in life sciences opportunities. Whether you have been waiting for improved market conditions to realize...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Novartis to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75B
GLP-1 Agonists May One Day Treat Prostate Cancer
Amgen shares soar as executives outline obesity drug push
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
Weight loss drugs and stomach paralysis: New findings

Share This Article